AR070323A1 - Polvo para suspension oral de un macrolido inmunosupresor - Google Patents

Polvo para suspension oral de un macrolido inmunosupresor

Info

Publication number
AR070323A1
AR070323A1 ARP090100290A AR070323A1 AR 070323 A1 AR070323 A1 AR 070323A1 AR P090100290 A ARP090100290 A AR P090100290A AR 070323 A1 AR070323 A1 AR 070323A1
Authority
AR
Argentina
Prior art keywords
powder
pharmaceutical compositions
suspension
oral suspension
immunosuppressor
Prior art date
Application number
Other languages
English (en)
Inventor
Monetta Rodrigo Ivan Ramirez
Original Assignee
Igloo Zone Chile S A
Gynopharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igloo Zone Chile S A, Gynopharma S A filed Critical Igloo Zone Chile S A
Publication of AR070323A1 publication Critical patent/AR070323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas que consisten en un polvo para suspension oral de tacrolimus que presenta gran estabilidad como polvo para suspension y también una vez preparada la suspension extemporánea sin la formacion de aglomerados de tipo torta (cake), de buen sabor y agradable aroma. También eI método de preparacion de las composiciones farmacéuticas, procedimiento en seco que consiste en mezclar durante un tiempo adecuado tacrolimus y los excipientes farmacéuticamente aceptables previamente tamizados, y el uso de las composiciones farmacéuticas para el tratamiento y prevencion del rechazo de transplante de árganos y dermatitis atopica.
ARP090100290 2008-02-05 2009-01-29 Polvo para suspension oral de un macrolido inmunosupresor AR070323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2008000374A CL2008000374A1 (es) 2008-02-05 2008-02-05 Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve

Publications (1)

Publication Number Publication Date
AR070323A1 true AR070323A1 (es) 2010-03-31

Family

ID=40261181

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100290 AR070323A1 (es) 2008-02-05 2009-01-29 Polvo para suspension oral de un macrolido inmunosupresor

Country Status (15)

Country Link
US (2) US20110021553A1 (es)
EP (1) EP2248522B1 (es)
JP (1) JP2011511059A (es)
CN (1) CN101977602A (es)
AR (1) AR070323A1 (es)
BR (1) BRPI0908072A2 (es)
CA (1) CA2714237A1 (es)
CL (1) CL2008000374A1 (es)
CO (1) CO6660422A2 (es)
EC (1) ECSP10010383A (es)
ES (1) ES2355884B1 (es)
MX (1) MX349358B (es)
PE (1) PE20091372A1 (es)
PT (1) PT2248522T (es)
WO (1) WO2009098649A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2773204A4 (en) 2011-10-31 2015-05-27 Glaxosmithkline Intellectual Property Ltd Pazopanib FORMULATION
CN115804760B (zh) * 2022-11-23 2024-07-30 无锡福祈制药有限公司 一种他克莫司纳米晶体胶囊剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
KR0177158B1 (ko) 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
TW570814B (en) * 1998-03-26 2004-01-11 Fujisawa Pharmaceutical Co Sustained-release pharmaceutical composition
AU2004267910B2 (en) 2003-08-29 2011-01-06 Veloxis Pharmaceuticals, Inc. Solid dispersions comprising tacrolimus
ES2376238T3 (es) 2003-08-29 2012-03-12 Veloxis Pharmaceuticals A/S Composiciones de liberación modificada comprendiendo tacrolimus.
KR100866728B1 (ko) 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
KR20070060144A (ko) * 2004-12-01 2007-06-12 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 결정체 마크로라이드의 제조 방법
KR100678829B1 (ko) 2004-12-06 2007-02-05 한미약품 주식회사 타크로리무스의 경구용 마이크로에멀젼 조성물
EP1835889A1 (en) * 2004-12-15 2007-09-26 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
HUP0600097A3 (en) 2006-02-08 2008-07-28 Richter Gedeon Nyrt Pharmaceutical compositions comprising tacrolimus and process for their preparation
US20100003332A1 (en) * 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
CN100515413C (zh) 2006-09-15 2009-07-22 杭州平和安康医药科技有限公司 他克莫司口服制剂

Also Published As

Publication number Publication date
CL2008000374A1 (es) 2008-04-04
EP2248522A4 (en) 2013-01-09
US20140088135A1 (en) 2014-03-27
WO2009098649A1 (es) 2009-08-13
US20110021553A1 (en) 2011-01-27
ECSP10010383A (es) 2010-11-30
CO6660422A2 (es) 2013-04-30
ES2355884B1 (es) 2012-01-24
CN101977602A (zh) 2011-02-16
MX2010008327A (es) 2010-11-30
PE20091372A1 (es) 2009-10-18
JP2011511059A (ja) 2011-04-07
CA2714237A1 (en) 2009-08-13
PT2248522T (pt) 2017-07-27
ES2355884A1 (es) 2011-04-01
BRPI0908072A2 (pt) 2015-07-21
EP2248522A1 (en) 2010-11-10
EP2248522B1 (en) 2017-05-03
MX349358B (es) 2015-08-25

Similar Documents

Publication Publication Date Title
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
WO2017048974A8 (en) Inhalable nicotine formulations, and methods of making and using thereof
WO2017127835A3 (en) Aqueous formulations and methods of preparation and use thereof
EA201290734A1 (ru) Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта
EP3863716A4 (en) Macrocyclic lactone formulations, methods of their preparation and use of the formulations in treating pathologies secondary to ophthalmic parasites
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
NZ605022A (en) Heterocyclic compounds, their preparation and their therapeutic application
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
WO2014100351A3 (en) 8'-hydroxy-dihydroergotamine compounds and compositions
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
IL268458A (en) Inhalable nicotine formulations, and methods of making and using thereof
EA201791411A1 (ru) Новая фармацевтическая композиция
AR070323A1 (es) Polvo para suspension oral de un macrolido inmunosupresor
WO2011101734A3 (en) Taste-masked powder for suspension compositions of methylprednisolone
MA50450A (fr) Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
PH12018500886A1 (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
RU2017102705A (ru) Композиции, содержащие мелатонин и флавоноиды, для использования в лечении опухолей, резистентных к химиотерапии
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
PT3215143T (pt) Combinação compreendendo espirulina e palmitoíletanolamida
PH12018502139A1 (en) Phosphaplatin liquid formulations
PH12016502540A1 (en) Pharmaceutical dosage forms
EP2863899B8 (en) Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process

Legal Events

Date Code Title Description
FB Suspension of granting procedure